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Abstract
Introduction: Dyslipidaemia is accompanied with increased cardiovascular events in diabetic patients. Today there have been some im-
provements in the management of dyslipidaemia using lifestyle modification and medications. In this study we evaluate the management
of dyslipidaemia in an academic centre.
Material and methods: This is a descriptive study, from January 2003 until December 2007. All type 2 diabetic patients who were more
than 30 years old and had at least 2 visits per year were eligible for including.
Results: Overall, 1179 patients (70.2% women) were assessed. Mean LDL-C in 2003 was 124.6 ± 34.6 mg/dL, and decreased to 109.7 ± 28.9
mg/dL in 2007 (p < 0.05). 21.0% of patients in 2003 and 40.5% of them in 2007 had LDL-C < 100 mg/dL. TG did not change during these
years. There was an increase in the use of statins from 76.3% to 84.3% (p-value < 0.05) during the 5 years since 2003, but a decrease in the
use of fibrates.
Conslusions: Although recently we have made improvements in the control of dyslipidaemia in diabetic patients, we have not reached
our goals. Of late, physicians have emphasized the use of statins in diabetic patients, which has resulted in much better levels of LDL-C,
but still less than half of the patients are at ideal levels. In conclusion, we should revise our point of view to begin and intensify treatment
of dyslipidaemia in diabetic patients, to achieve the goal of treatment and prevent cardiovascular events optimally.
(Pol J Endocrinol 2009; 60 (5): 353–356)
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Streszczenie
Wstęp: Dyslipidemia u chorych na cukrzycę wiąże się ze zwiększoną częstością zdarzeń sercowo-naczyniowych. W leczeniu dyslipidemii
obejmującym modyfikację stylu życia i farmakoterapię nastąpił znaczny postęp. Celem niniejszego badania była ocena leczenia dyslipide-
mii w ośrodku akademickim.
Materiał i metody: Badanie obejmowało okres od stycznia 2003 roku do grudnia 2007 roku. Do badania włączono wszystkich chorych na
cukrzycę typu 2 w wieku powyżej 30 lat, którzy odbywali co najmniej 2 wizyty rocznie.
Wyniki: Oceniono łącznie 1179 chorych (70,2% stanowiły kobiety). Średnie stężenie cholesterolu frakcji LDL w 2003 roku wynosiło 124,6
± 34,6 mg/dl. Uległo ono obniżeniu i wynosiło 109,7 ± 28,9 mg/dl w 2007 roku (p < 0,05). Odsetek chorych, u których stężenie cholesterolu
frakcji LDL było niższe niż 100 mg/dl wynosił 21,0% w 2003 roku i 40,5% w 2007 roku. Stężenie triglicerydów nie zmieniło się w tym
okresie. W okresie 5 lat od 2003 roku nastąpiło zwiększenie częstości stosowania statyn z 76,3% do 84,3% (p < 0,05), zmniejszyło się
natomiast zużycie fibratów.
Wnioski: Mimo że w ostatnich latach nastąpiła poprawa w zakresie kontroli stężenia lipidów u chorych na cukrzycę, nadal rzadko udaje
się osiągnąć cele terapii. W najnowszych doniesieniach podkreśla się, że stosowanie statyn u chorych na cukrzycę powoduje znaczne
obniżenie stężenia cholesterolu frakcji LDL, jednak docelowe wartości uzyskuje nadal mniej niż połowa pacjentów. Podsumowując,
należy zrewidować dotychczasowe poglądy na temat leków hipolipemizujacych i wcześniej rozpoczynać intensywną terapię dyslipide-
mii u chorych na cukrzycę, aby osiągnąć cele leczenia i zapewnić optymalną prewencję zdarzeń sercowo-naczyniowych.
(Endokrynol Pol 2009; 60 (5): 353–356)
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The prevalence of diabetes mellitus (DM) is increasing
around the world [1]. Today we know that diabetes
mellitus is a metabolic disorder that is associated with
hyperglycaemia, hypertension, dyslipidaemia, and in-
sulin resistance. Dyslipidaemia in DM is defined by ele-
vated triglycerides (TG), low high-density lipoprotein
cholesterol (HDL-C), and small dense low-density li-
poprotein cholesterol (LDL-C) particles. Total choleste-
rol and LDL-C concentration is usually similar to that
found in the general population [2–4].
This lipid deregulation is accompanied by elevated
cardiovascular disease risk [5]. In the UK prospective
diabetes study, 49% of deaths in diabetics within 10 years
were due to cardiovascular events [6]. Data such as the-
se show the significance of controlling dyslipidaemia
as a cardiovascular risk factor in diabetic patients. Re-
sults from recent trials show a reduction of cardiova-
scular disease in patients who receive lipid-lowering
therapy in the context of both primary and secondary
prevention [7–9].
It has been shown that, although increasing num-
bers of diabetic patients are tested for dyslipidaemia,
fewer patients reach target goals [10–12]. Data from
Eastern countries also show poor control of dyslipida-
emia in diabetes mellitus [13–15]. The aim of the pre-
sent study was to evaluate dyslipidaemia and its mana-
gement among type 2 diabetics in a Middle Eastern
population in an academic centre in Iran, and to com-
pare this with other countries.
Material and methods
In this descriptive study we evaluated diabetic patients
in an ambulatory setting in the Endocrinology and
Metabolism Research Centre (EMRC) of Isfahan Uni-
versity of Medical Science from January 2003 to Decem-
ber 2007.
Patients were eligible for inclusion if they were more
than 30 years of age, had type 2 diabetes mellitus, and
had at least two visits per year. This clinic included both
primary and specialty practices.  Patients were referred
to the centre by physicians from around the town; all
the patients had files in the centre, including all of the
follow up data obtained during regular visits. The phy-
sicians were trained general practitioners and interni-
sts. The follow up of patients in this centre was in ac-
cordance with the American Diabetes Association (ADA)
guidelines. Overall, 1179 patients were evaluated for
blood pressure, lipid profiles, HbA1c, and course of tre-
atment.
Data were collected from computerized forms in the
centre. For each patient, all the venous blood samples
were collected after 8 hours of fasting, and were analy-
zed using an enzymatic method. The results were sa-
ved in a central computer.
Statistical methods
Data are presented as mean (±SD) values for continu-
ous variables. Lipid profiles were classified as control-
led and uncontrolled, according to ADA guidelines, i.e.
LDL-C < 100 mg/dL, Total cholesterol < 200 mg/dL,
HDL > 40 mg/dL, and TG < 150 mg/dL. HBA1c was con-
sidered acceptable when it was less than 7 percent.
Coronary artery disease was selected as a major ma-
crovascular outcome of diabetes and hyperlipidaemia
and their treatment aim. It was defined as positive if
the patient developed some kind of acute coronary syn-
drome, including myocardial infarction, unstable angina
pectoris, investigated, cardiologist-approved or corona-
ry angiogram-proven stable angina and its equivalents,
and sudden cardiac death.
Comparisons between means of variables between
different measurement times were performed using
paired student t-test. Correlation of continuous quanti-
tative variables, including lipid levels, HBA1c, and BMI,
was calculated using linear regression after establishing
essential data characteristics. Classified lipid levels and
HBA1c as well as CAD were cross tabulated, and Chi-
square tests were utilized to establish possible effects.
All comparisons were considered as significant at
p < 0.05. Analysis was done using SPSS statistical pac-
kage version 13.
Results
Body mass index increased minimally by about 0.36 kg/m2
during the period from 2003 to 2007 (p < 0.01). Systolic
and diastolic blood pressure were decreased respecti-
vely (mean Systolic blood pressure: 137.9 ± 17 mm Hg
to 131.7 ± 19 mm Hg; Mean diastolic blood pressure:
88.4 ± 9 mm Hg to 82.0 ± 10 mm Hg).
Overall, 70% of patients were dyslipidemic, (total
cholesterol ≥ 200 mg/dl or LDL-C ≥ 100 mg/dL or tri-
glycerides ≥ 150 mg/dL) a result which was similar to
other reports.
Mean of LDL-C in 2003 was 124.6 ± 34.6 mg/dL and
decreased to 109.7 ± 28.9 mg/dL in 2007 (p-value < 0.05).
Of course, this decrease of LDL-C was associated with
increase of TG from 181.7 ± 120.5 mg/dL in 2003 to 191.0 ±
± 89.2 mg/dL in 2005 (p-value < 0.05), but again decre-
ased to 174.7 ± 76.1 mg/dL in 2007.
HDL-C did not change significantly (mean = 44.5 ±
± 10.6 mg/dL) but total cholesterol also decreased from
199.07 ± 66.5 mg/dL to 184.8 ± 60.0 mg/dL (p-value
< 0.05) during these years, so HDL/cholesterol ratio in-
creased from 22.25% to 24.47% (p < 0.01). These chan-
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ges were seen in all age groups and there were no dif-
ferences between men and women.
In the year 2003, the mean of HbA1c was 7.9 ± 1.7%
and was not significantly altered in year 2007
(7.6%±1.5%). During the follow-up period, HBA1c was
negatively but weakly correlated with LDL, total Cho-
lesterol, and TG levels (r was 0.139, 0.178, and 0.174, re-
spectively; p < 0.05). When HBA1c level less than 7 per-
cent was set as the optimal goal, patients with accepta-
ble HBA1c had significantly more chance to have con-
trolled TG level in 2003, i.e. 56 percent of those with
good HBA1c had TG under 150 mg/dL whereas 38 per-
cent of uncontrolled HBA1c cases had acceptable TG
(p < 0.01). Similar findings, but to a lesser extent, were
seen for total cholesterol (61 and 52%, respectively) but
not for LDL (p = 0.113). This relation changed in 2007
for cholesterol, and absolute reduction in risk of effect
of HBA1c on total cholesterol deceased to 5 percent due
to HBA1c.
All of the dyslipidemic patients in this centre were
treated with lifestyle modification and medications such
as statins, fibrates, or both (Table I).  As shown in table 1,
use of statins (as opposed to fibrates) has increased du-
ring recent years, and the number of patients who re-
ach the goal of treatment according to ADA guidelines
(LDL-C < 100 mg/dL, Total cholesterol<200 mg/dL,
HDL > 40 mg/dL) has increased (Table II). This state-
ment was not shown to be correct for TG (Fig. 1). It was
shown that being in a controlled TG state in 2003 was
a predictor of TG control status in 2008; 72% of those
with under 150 mg/dL TG remained controlled in 2007.
The rate of development of CAD at the end of the
follow-up period was lower in those with optimal LDL
than uncontrolled LDL levels (32% v. 60%); optimal
cholesterol also negatively affected CAD incidence (39%
v. 60%).
Discussion
In this observational study, we showed an increased
use of statins as lipid lowering agents, and consequen-
tly better control of lipids between 2003 and 2007 in the
general diabetic population. This improvement due to
use of statins, not fibrates, resulted in a decrease of LDL-C
but not of TG, a finding that may have been assumed
previously due to the pharmacological characteristics
of statins. It was also reconfirmed in our findings when
we found a strong correlation of start time and end time
TG control status.
Other factors like HbA1C, systolic, and diastolic blo-
od pressure also improved during these years, but still
are not ideal to any significant degree. Less than half of
the patients had HbA1c < 7%, which was similar to other
studies, and for blood pressure, the results were much
better; about 57% of patients had BP less than 130/80
mm Hg, although it was better than in some other stu-
dies [11–15].
LDL-C was less than 100 mg/dL in about 40% of our
patients in 2007. One study in Kuwait has shown that
LDL-C less than 100 mg/dL was seen in 14% of diabetic
patients in an outpatient clinic [16]. Another study in
the US has shown that 46.1% of diabetic patients of aca-
demic centres had LDL-C less than 100 mg/dL [11]. This
means that we have improved the control of dyslipida-
emia much better than our neighbouring countries.
Despite these generally favourable improvements
in the management of dyslipidaemia in diabetic patients
and the use of lipid lowering agents in about 84% of
patients, only 40.6% have ideal LDL-C. This might po-
Table I. Drug treatment in 2003 and 2007
Tabela I. Stosowanie leków w latach 2003 i 2007
% of patients 2003 2007 p-value
who receive
Statin 76.3% 84.3% 0.02
Fibrate 20.5% 6.5% 0.00
Both 3.2% 9.2% 0.00
Figure 1. Trends in LDL-C and TG levels during 5 years
Rycina 1. Zmiany stężeń cholesterolu frakcji LDL i triglicerydów
w ciagu 5 lat
Table II. Patients at goal of treatment in 2003 and 2007
Tabela II. Odsetek chorych, u których osiągnięto cele leczenia
w latach 2003 i 2007
% at goal 2003 2007 p-value
HbA1c 32.8% 36.4% 0.08
Blood pressure 29.6% 50.6% 0.00
LDL-C 21.0% 40.5% 0.00
TG 43.2% 42.7% 0.8
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ssibly show that although our physicians start the li-
pid-lowering agents they do not intensify the agent
according to the patients lipid levels, or perhaps the
maximal drug effect does not match acceptable lipid
levels in some. This may be investigated in future stu-
dies regarding the dose-effect relation for statin-lipid
model and drug efficacy in our setting.
One interesting result of the present study was the
discovery of a weak correlation between HBA1c and li-
pid profiles. This finding was also previously reported
by Khan [17] and Grant [18]. Surely, when the data of
HBA1c become left skewed (i.e. the major proportion
of patients are distributed within the lower levels of
HBA1c), then the expected correlation would not be lar-
ge. In the other words, when you achieve relatively
optimal goals in glycaemic control, other means must
be used to improve patient outcome.
Several causes have been proposed regarding why
physicians do not prescribe enough drugs [19–22]. One
problem is that they might be afraid of side effects of
the combination of statin and fibrates. The use of sta-
tins in diabetic patients has been emphasized recently
resulting in a decrease in use of fibrates (20.5% to 6.5%
between 2003 and 2007); only 9.2% of patients received
both drugs that resulted in no improvement of TG le-
vel between 2003 and 2007.
In our next study we would like to evaluate the ef-
fect of dosage and intensification of medications in dys-
lipidaemic patients. A limitation of this study is that we
assessed the management of dyslipidaemia within a
group of diabetic patients in an academic centre, and
also that we chose patients with regular visits. So, it does
not show the situation in the whole diabetic popula-
tion.
Another limitation is that we do not have enough
data from non-diabetic patients to compare the results.
A strength of this study is that the data were collected
over a 5-year period, enabling the assessment of trends
in lipid levels.
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